The introduction of a new generation of gene panels into clinical practice has revolutionized the study of hereditary colorectal cancer (CRC) syndromes. Techniques have evolved from the sequencing of individual genes to simultaneous sequencing with massive sequencing platforms, which allows for reducing time as well as costs. However, this increases the difficulty of interpretation and genetic counseling, as multiple mutations with different degrees of clinical applicability are detected. For this reason, it is necessary to establish recommendations on their use. Given the lack of consensus, several societies have created a position paper which establishes guidelines to be followed for both nonpolyposis CRC and polyposis syndromes.